AlicaforsenAlicaforsen is currently under license by Atlantic Pharmaceuticals Limited. The drug is administered by enema and is being tested for use in ulcerative colitis and pouchitis. Alicaforsen has been granted orphan drug status in the United States and the European Union.
AlequelEnzo Biochem has completed a study of Alequel in patients with moderate to severe Crohn’s disease. The drug is a personalized treatment of a protein-containing extract that is created from tissue from the patient’s colon and administered orally. Remission was achieved by 50 percent of patients on the drug, versus 33 percent with a placebo. The drug was well tolerated, with no adverse effects.
TeduglutideThis new compound is being studied for use in both IBD and short bowel syndrome (SBS). SBS is a condition that causes diarrhea, cramping, bloating, and heartburn that occurs in people who have had half (or more) of their small intestine removed. The most common cause of SBS is repeated resection surgeries used to treat Crohn’s disease.
Side effects of teduglutide appear to be minimal, as the effects occur mainly in the intestinal tract. People with SBS who participated in a trial of teduglutide showed both increased nutrient intake and body weight. Commonly reported adverse effects included abdominal pain, headache, stoma changes, and swelling.
NPS Pharmaceuticals, the developer of teduglutide, completed a proof-of-concept study in patients with Crohn's disease. Of the patients with Crohn's, 55 percent had achieved remission after 8 weeks of using the drug, compared to 33 percent of the patients receiving a placebo. The most reported adverse effect was redness at the location of the injection. Another study is being conducted on patients with SBS.
Teduglutide has been granted orphan drug status in both the United States and Europe for its use in SBS. NPS is currently looking for a development partner to continue testing the drug for use in Crohn’s disease.
Traficet-EN (CCX282)Traficet-EN is an anti-inflammatory small molecule therapeutic which is currently being tested for use in Crohn's disease by it's manufacturer, ChemoCentryx. In the latest trial (PROTECT-1), a greater percentage of patients receiving the drug achieved remission after 36 weeks than those that received the placebo. The drug was well tolerated among the study participants over the course of the 12 month trial.
ChemoCentryx. "CCR9 Program.". 2010. 26 June 2010.
Enzo Biochem, Inc. "Alequel.". 2010. 26 June 2010.
Isis Pharmaceuticals, Inc. "Inflammatory Disease.". 2010. 26 June 2010.
Margalit M, Israeli E, Shibolet O, Zigmond E, Klein A, Hemed N, Donegan JJ, Rabbani E, Goldin E, Ilan Y. "A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach." Am J Gastroenterol March 2006 101:561-568. 26 June 2010.
NPS Pharmaceuticals. "NPS Partnering Opportunities." 2010. 26 Feb 2012.